Mutual of America Capital Management LLC Trims Stake in Zimmer Biomet Holdings, Inc. $ZBH

Mutual of America Capital Management LLC trimmed its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.0% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,733 shares of the medical equipment provider’s stock after selling 468 shares during the period. Mutual of America Capital Management LLC’s holdings in Zimmer Biomet were worth $2,073,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of ZBH. Brighton Jones LLC purchased a new stake in shares of Zimmer Biomet in the 4th quarter worth $204,000. GAMMA Investing LLC increased its stake in shares of Zimmer Biomet by 52.4% in the 1st quarter. GAMMA Investing LLC now owns 3,502 shares of the medical equipment provider’s stock worth $396,000 after purchasing an additional 1,204 shares in the last quarter. Oppenheimer Asset Management Inc. increased its stake in shares of Zimmer Biomet by 6.6% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 10,923 shares of the medical equipment provider’s stock worth $1,236,000 after purchasing an additional 672 shares in the last quarter. Asset Management One Co. Ltd. boosted its holdings in Zimmer Biomet by 2.0% in the 1st quarter. Asset Management One Co. Ltd. now owns 83,548 shares of the medical equipment provider’s stock worth $9,456,000 after buying an additional 1,635 shares during the period. Finally, Golden State Wealth Management LLC boosted its holdings in Zimmer Biomet by 103.0% in the 1st quarter. Golden State Wealth Management LLC now owns 1,411 shares of the medical equipment provider’s stock worth $160,000 after buying an additional 716 shares during the period. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Stock Down 0.0%

ZBH opened at $103.14 on Friday. The firm has a 50-day simple moving average of $101.86 and a two-hundred day simple moving average of $97.68. Zimmer Biomet Holdings, Inc. has a 52 week low of $89.22 and a 52 week high of $114.72. The company has a market capitalization of $20.43 billion, a PE ratio of 25.09, a price-to-earnings-growth ratio of 2.37 and a beta of 0.67. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $1.98 by $0.09. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The firm had revenue of $2.08 billion during the quarter, compared to the consensus estimate of $2.06 billion. During the same quarter last year, the firm earned $2.01 EPS. The firm’s revenue for the quarter was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be issued a $0.24 dividend. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.9%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 23.36%.

Insider Activity at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,500 shares of the stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $104.15, for a total value of $156,225.00. Following the completion of the transaction, the senior vice president owned 6,833 shares of the company’s stock, valued at approximately $711,656.95. This trade represents a 18.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.39% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently weighed in on ZBH. BTIG Research upped their target price on shares of Zimmer Biomet from $118.00 to $122.00 and gave the stock a “buy” rating in a report on Monday, October 13th. Canaccord Genuity Group reaffirmed a “hold” rating and issued a $101.00 target price on shares of Zimmer Biomet in a report on Wednesday. Rothschild Redb raised shares of Zimmer Biomet to a “strong-buy” rating in a report on Thursday, September 18th. Royal Bank Of Canada set a $111.00 target price on shares of Zimmer Biomet in a report on Friday, October 10th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zimmer Biomet in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $111.94.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.